Russian Heart Failure Journal 2009year Effect of Preductal MB treatment on the course of CHF in patients with stable exertion angina after acute myocardial infarction.Results from the study PRIMA


To access this material please log in or register

Register Authorize
2009/

Effect of Preductal MB treatment on the course of CHF in patients with stable exertion angina after acute myocardial infarction.Results from the study PRIMA

Vasyuk Yu. A., Shkolnik E. L., Kulikov K. G., Lebedev E.V., Shalnova S. A.

Keywords:

DOI:

Urgency. Despite considerable achievements in understanding of mechanisms for development and progression of CHF, patient survival and quality of life remain unsatisfactory. This is why active search for new approaches to prevention and treatment of heart failure is continuing. Aim. Evaluating the efficacy and safety of trimetasidine 35 mg twice daily in combination with commonly accepted standard therapy. Materials and methods. Clinical part of the study was performed in 41 regions of the Russian Federation in 2007. Study enrolled 876 patients aged from 31 to 82 years who had MI at least 12 months prior to enrollment, with stable II or III FC exertion angina. Patients were randomized to two groups: the trimetasidine treatment group included 751 (79.2%) patients; the control group included 197 (20.8%) patients. CHF was diagnosed in 77% of patients in the trimetasidine treatment group and in 80.7% of patients in the control group. Results. The total number of patients with CHF considerably decreased in the trimetasidine treatment group, and the severity of CHF reduced. Such CHF symptoms as fatigue, dyspnea and leg edema were statistically significantly reduced compared to the control group.
  1. Мареев В. Ю. Результаты наиболее интересных исследований по проблеме сердечной недостаточности. Сердечная Недостаточность. 2000; 1 (1):8–18
  2. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998; 97 (3):282‑289.
  3. Агеев Ф. Т., Скворцов А. А., Мареев В. Ю., Беленков Ю. Н. Сердечная недостаточность на фоне ишемической болезни сердца: некоторые вопросы эмидемиологии, патогенеза и лечения. Русский медицинский журнал. 2000; 2 (15–16):622‑626.
  4. Бурлова Е. С., Провоторов В. М. Течение и лечение хронической сердечной недостаточности у лиц пожилого возраста. Российские Медицинские вести. 2007; 12 (3):9–17.
  5. Фомин И. В., Беленков Ю. Н., Мареев В. Ю. и др. Распространенность ХСН в Европейской части Российской Федерации – данные ЭПОХА-ХСН. Журнал Сердечная Недостаточность. 2006; 7 (1):4–7.
  6. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Даниелян М. О. Первые результаты национального эпидемиологического исследования – эпидемиологическое обследование больных ХСН в реальной клинической практике (по обращаемости) – ЭПОХА-О-ХСН. Журнал Сердечная Недостаточность. 2003; 4 (3):116‑121.
  7. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J. 2001; 22 (23):2164–2170.
  8. Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart. 2005; 91 (2):161‑165.
  9. Bozkurt B, Mann DL. Use of biomarkers in the management of heart failure: are we there yet? Circulation. 2003; 107 (9):1231–1233.
  10. Fragasso G, Palloshi A, Puccetti P et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol. 2006; 48 (5):992‑998.
  11. Fragasso G, Piatti Md PM, Monti L et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003; 146 (5):E18.
  12. Маколкин В. И., Бузиашвили Ю. И., Осадчий К. К. и др. Сравнение эффективности реваскуляризации и медикаментозной терапии с применением триметазидина в восстановлении функций «спящего» («гибернирующего») миокарда. Кардиология. 2001; 41 (5):18–24.
  13. El-Kady T, El-Sabban K, Gabaly M et al. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24‑month study. Am J Cardiovasc Drugs. 2005; 5 (4):271‑278.

To access this material please log in or register

Register Authorize
Ru En